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Amygdalin isolated from Amygdalus mongolica protects against 
hepatic fibrosis in rats
The aim of this research was to investigate the effect of 
amygdalin on hepatic fibrosis in rats. Amygdalin was puri-
fied and identified from the seeds of Amygdalus mongo lica. 
Sprague Dawley rats in the control and model groups were 
administered water. Sprague Dawley rats were divided 
into the low-, middle-, and high-dose amygdalin groups 
that received 20, 40, and 80 mg kg–1 amygdalin, respective-
ly. whereas the silymarin group was treated with 50 mg 
kg–1 silymarin. The control and model groups were admin-
istered water. Liver tissue analysis revealed significantly 
lower activities of ALT, AST, ALP, SOD, and MDA in the 
drug-treated groups compared to the model group. Serum 
analysis revealed significantly lower HYC and C-IV in the 
middle-dose amygdalin-treated group compared to the 
model group. The histopathological changes were less se-
vere in the drug-treated groups as observed by the forma-
tion of pseudolobuli and decreased collagen fiber deposi-
tion. Hepatic fibrosis-related genes were expressed at 
significantly lower levels in the amygdalin-treated groups 
than in the model group. Amygdalin from A. mongolica 
 represents a therapeutic candidate for hepatic fibrosis pre-
vention and treatment. 
Keywords: amygdalin, Amygdalus mongolica, hepatic fibrosis, 
rat model, traditional Chinese medicine
Liver fibrosis occurs in response to a variety of insults, especially chronic injuries 
 including viral hepatitis, alcohol abuse, drug use, autoimmune attack of hepatocytes or bile 
duct epithelial cell, or congenital abnormalities (1). Both quantitative and qualitative changes 
in the composition of the hepatic extracellular matrix happen as the liver becomes fibrotic. 
Hepatic fibrosis can lead to irreversible cirrhosis, which involves multiple cellular and 
 molecular events (2). If properly treated at the fibrotic stage, cirrhosis can be prevented. 
However, if the treatment is not timely, the disorder can even lead to liver cancer (3). 
 Although the antifibrotic activities of many compounds have been demonstrated in animal 
models, none of these compounds has been thoroughly validated in the clinic or commer-
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armeniacae, a traditional Chinese medicine. Studies have found that this cyanogenic glyco-
side compound is widely used to inhibit fibrosis of the lungs, kidneys, and liver (5, 6).
Amygdalin can be found in a variety of plant species, specifically in rosaceous plant 
seeds, including apricot, cherry, plum, and peach seeds (7). Amygdalus mongolica (Maxim.) 
Ricker (Rosaceae) is a native plant of the Inner Mongolia plateau where it is known as 
Wulian-Buyilesi (8, 9). A. mongolica contains various nutrients including flavonoids, pro-
teins, fats, phenols, organic acids, polysaccharides, and vitamin E, all of which are also 
used the Chinese medicine (10, 11). Numerous studies have documented that amygdalin 
possesses the ability to induce cell apoptosis. Amygdalin has been used to treat different 
types of cancers and organ fibrosis. Guo et al. (12) unequivocally determined that amygda-
lin is a potent antifibrotic agent that may have therapeutic potential for patients with 
 fibrotic kidney diseases. Luo et al. (13) elucidated the mechanism by which amygdalin 
 reduces liver fibrosis; its role in regulating the expression of platelet-derived growth factor 
has been investigated. Hepatic fibrosis is considered to be a major global health issue due 
to the high morbidity, severe economic burden, and psychological pressure that it causes. 
Because there is still a lack of effective drugs and therapeutic strategies, this study exam-
ined the antifibrotic effect of amygdalin from A. mongolica seeds on hepatic fibrosis.
EXPERIMENTAL
Materials
The seeds of A. mongolica were collected from the Alashan Yabrai Gobi in Inner Mon-
golia in June 2016. The dry, mature seeds were identified by Professor Songli Shi of Baotou 
Medical College. The seeds of A. mongolica were placed in a drying oven at 55 °C for 8 h 
followed by cleaning, shelling, and crushing.
High-purity grade amygdalin was purchased from (Shanghai, China). The silymarin 
capsules were purchased from Madaus AG (Germany). The malondialdehyde (MDA) kit, 
superoxide dismutase (SOD) kit, hydroxyproline (HYP) kit, alanine aminotransferase 
(ALT) kit, aspartate aminotransferase (AST) kit, alkaline phosphatase (ALP) kit, Masson 
kit, and total protein quantitative assay kit were purchased from Jiancheng Biology Engi-
neering Institute (China). The hyaluronic acid (HA) kit, laminin (LN) kit, procollagen III 
(PC-III) kit, and collagen IV (C-IV) kit were purchased from Beijing North Institute of 
Biotechnology (China). The TRIzol kit, RevertAid First Strand cDNA Synthesis Kit, and 
Real SYBR Mixture kit were purchased from Thermo Fisher Scientific (China).
Isolation and identification of amygdalin in A. mongolica
Amygdalin was isolated from A. mongolica seeds for the first time in our laboratory 
(14). Crushed A. mongolica seeds were dissolved in 95 % ethanol (1:10 g mL–1) and extracted 
using a Soxhlet apparatus three times for 2 h each. A rotary evaporator and water bath 
were used to concentrate the crude extract to an oily residue. According to the solvent 
polarity by liquid/liquid extraction, petroleum ether, ethyl acetate, n-butanol, and water 
were successively used to extract the less polar substances from the oily residue. The yield 
of the n-butanol extraction sites to the oily residue was 41.87 %.
The n-butanol extraction sites were applied to a D101 macroporous resin column and 
eluted with 10, 30, 50, 70, and 90 % ethanol. Thin-layer silica gel chromatography was per-
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formed to assess the elution steps. Carbon tetrachloride and methanol were combined (4:1) 
as the developing solvent. The 10 and 30 %-alcohol eluates were loaded on an octadecyl-
silyl (ODS) column for gradient elution with methanol (10, 20, 30, 40, 50, 60, 70, 80, 90, and 
100 %). The developing solvent contained ethyl acetate, formic acid, and water (20:3:1). 
 Finally, a colorless powder designated compound I was obtained by pooling the fluxes 
with the same chromatographic characteristics and recovering the solvent.
The structural identification of the colorless powder as compound I was performed by 
the Inner Mongolia Key Laboratory of Fine Organic Synthesis at Inner Mongolia University. 
The ultra-performance liquid chromatography (UPLC) conditions were as follows: Agilent 
ZORBAX Eclipse Plus C18; the mobile phase A was 0.1 % formic acid in aqueous solution, 
the mobile phase B was methanol, and the flow rate was 0.4 Ml min–1; the elution gradient 
was 0–3 min 10–30 % B, 4–5 min 30–100 % B, 5–6 min 100 % B. The electron spray ionization-
mass spectrum (ESI-MS) conditions were as follows: negative ion mode; debris voltage of 
50 V; capillary voltage of 3500 V; atomization pressure of 45 psi; drying gas temperature of 
350 °C; mass spectrometry ion range of 100–1500 m/z. The nuclear magnetic resonance 
(NMR) conditions were as follows: D2O as the solvent, frequency at 500 MHz.
Animals and hepatic fibrosis model establishment
Sixty male Sprague Dawley (SD) rats, SPF grade, bodyweight 170–200 g, were pur-
chased from the Peking University Health Science Center (Laboratory Animal Science 
Department), license No. 2011-0012 (Beijing) SCXK and used in the hepatic fibrosis experi-
ments. All rats were housed in an animal room at a controlled temperature of 25 ± 2 °C and 
a relative humidity of 55 %. All procedures involving rats were approved by the Commit-
tee on the Ethics of Animal Experiments of the Institute, Baotou Medical College, Baotou, 
Inner Mongolia, China. All efforts were made to minimize animal suffering.
The animals were fed a basic diet for one week to adapt to the new living environ-
ment. Subsequently, the rats were randomly divided into 6 groups (the Control, Model, 
Low-Dose, Middle-Dose, High-Dose, and Silymarin groups) with 10 rats/group.
The rat hepatic fibrosis model was established as previously described (15–17). The 
rats received subcutaneous injections of carbon tetrachloride (CCl4), 5 mL kg–1 as an initial 
dose and 3 mL kg–1 as subsequent doses, dissolved in 40 % olive oil 2 times per week for 
Table I. Body mass, liver/spleen ratio of rats in different groups
Groupa Body mass (g) Liver/Spleen ratio
Control 438.86 ± 14.75 14.82 ± 0.94
Model 339.83 ± 22.58* 24.52 ± 1.82*
Low-dose 365.86 ± 21.45*# 19.16 ± 2,70*#
Middle-dose 392.67 ± 24.55*# 23.64 ± 2.76*
High-dose 352.50 ± 21.45* 22.80 ± 3.37*
Silymarin 372.33 ± 24.67*# 22.95 ± 1.79*
a The number of rats in each group was 10; * significant from control p < 0.05; # significant 
from model p < 0.05.
462
J. Wang et al.: Amygdalin isolated from Amygdalus mongolica protects against hepatic fibrosis in rats, Acta Pharm. 71 (2021) 459–471.
 
8 weeks. The rats in the control group without CCl4 treatment remained healthy during 
this period. In the CCl4 treatment groups, the body mass was significantly decreased but 
the liver/spleen ratio was significantly increased compared to the corresponding values in 
the untreated control group (Table I). Therefore, a rat model of hepatic fibrosis was success-
fully established.
Drug delivery, serum parameter measurements, and liver histopathological examination
The LD50 (lethal dose causing 50 % survival in a group) of amygdalin was determined 
in a series of five experiments, each using 60 rats. The amygdalin doses ranged from below 
400 mg per kg of body weight to above 1,100 mg per kg of body mass. The results showed 
that the LD50 of amygdalin was approximately 522 mg kg–1 (18). Three groups received 20, 
40, 80 mg kg–1 amygdalin as the low-, middle-, or high-dose, respectively, whereas one 
comparator-treated group received silymarin (50 mg kg–1). The treatments were adminis-
tered by gavage of 5 mL kg–1 amygdalin or silymarin solution into the stomach. The low-, 
middle-, and high-amygdalin dose groups were treated with 4, 8, and 16 mg mL–1 amyg-
dalin, respectively. The concentration of the silymarin solution was 10 mg mL–1. The rats 
in the model group and the control group received 5 mL kg–1 distilled water. Treatments 
were performed 2 times a week for 8 weeks.
After the intraperitoneal injection of 10 % chloral hydrate, blood samples were drawn 
from the abdominal aorta into heparinized injectors and centrifuged at 6,000 rpm for 10 
min at 4 °C. Liver function indexes, including ALT, AST, ALP, HYP, HA, LN, PC-III, C-IV, 
SOD, and MDA, were detected in the serum or liver tissues according to the instructions 
of the respective kits.
After finishing the blood collection, liver samples were dissected, washed with ice- 
-cold saline, and immediately stored at –80 °C until further analysis. Partial liver samples 
(1.0 × 1.0 × 0.3 cm liver tissue from the middle part of the right lobe of the liver) from each 
rat were fixed in 10 % neutral formalin and embedded with paraffin. All the specimens 
were sectioned at thicknesses of 4 μm. To conduct the histopathology analysis, hematoxy-
lin and eosin (H&E) and Masson’s staining were used. Images of the histopathological 
samples from each group were examined by a pathologist.
RNA isolation and quantitative real-time PCR (RT-PCR) analysis
Total RNA was extracted from liver tissue using the TRIzol kit according to the manu-
facturer’s instructions. The gene-specific primers were designed using Primer Premier 
5.0 software (Table II). The reverse transcription reactions were performed with the Revert 
Table II. The primer of qRT-PCR
Gene Name Forward (5′-3′) Reverse (5′-3′)
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Aid First-Strand cDNA Synthesis Kit following the manufacturer’s instructions. RT-PCR 
was performed with a 7900HT RT-PCR instrument (ABI company) using the Real SYBR 
Mixture kit. The thermal cycling conditions were as follows: initial denaturation at 95 °C 
for 35 s, then 40 cycles of denaturation at 95 °C for 5 s, followed by annealing and extension 
at 60 °C for 20 s. Quantitative expression changes were calculated using the 2−ΔΔCT method.
Statistical analysis
The experimental data were examined using SPSS 17.0 software for statistical data 
processing. To determine statistically significant differences, the data were subjected to 
one-way analysis of variance (ANOVA) and the least significant difference (LSD) post hoc 
test. The criterion for significance was set at p < 0.05.
RESULTS AND DISCUSSION
Compound structure identification
The main constituent of compound I was identified as amygdalin by UPLC-ESI-MS 
and NMR. The UPLC chromatogram showed that the n-butanol extraction sites had a peak 
at a retention time of 2.2 min. The product-ion spectra from the ESI-MS analysis identified 
the following product-ions: [M-H]–, m/z 456; [M+COOH]–, m/z 502; and [M-C2H2]–, m/z 431. 
The results characterized compound I as a small molecule with a relative molecular mass 
of 457, suggesting that it is a cyanogenic glycoside (Fig. 1).
Fig. 1. UPLC analysis of the purified extract: a) UPLC chromatogram of the purified extract; b) ESI-MS 





J. Wang et al.: Amygdalin isolated from Amygdalus mongolica protects against hepatic fibrosis in rats, Acta Pharm. 71 (2021) 459–471.
 
The 1H NMR analysis (D2O, 500 MHz) data showed monosubstituted benzene ring 
signals at δ 7.43 (2H, m, H-2,6), 7.36 (3H, m, H-3,4,5), a continuous oxygen methylene signal 
at δ 5.89 (1 H, s, H-7), and two molecular glucose signals at δ 4.65 (l H, d, J = 8.1 Hz, H-15) 
and 4.62 (l H, d, J = 7.5 Hz, H-9). The 13C NMR spectrum data indicated the presence of 
three rings (Table III). The NMR data were consistent with the reported characterization 
of amygdalin, indicating that the compound I preparation contains amygdalin.
Solid crystallization was obtained by combining the flow fraction containing the same 
composition and recovering the solvent. Finally, the content of amygdalin in the n-butanol 
extraction sites of A. mongolica was 47.72 %.
Effects of amygdalin on the activities of ALT, AST, and ALP
Hepatic fibrosis is a reversible pathological process that acts as a repair response to 
chronic liver injuries (19). Li et al. (20) found that the increase in ALT, AST, and ALP in the 
serum indicates severe liver damage. Measurements of the activity levels of ALT, AST, 
 and ALP, which are serum markers of liver function, indicated that these three enzymes 
Table III. 13C NMR data of compound I
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exhibited higher activities in the model group than in the control group (Fig. 2). As indicators 
of drug efficacy in this animal model, the activities of these three enzymes were signifi-
cantly decreased in the groups treated with silymarin and different doses of amygdalin, 
compared with those in the model group (p < 0.05). Compared with that in the silymarin 
group, only the ALP value in the high-dose group showed a significant difference (p < 0.05), 
and the other indexes showed no significant difference. Therefore, amygdalin from A. mongo-
lica alleviated the extent of hepatic fibrosis to varying degrees.
Effects of amygdalin on the content of HYP
It was reported that elevated HYP levels had the best potential for predicting liver 
fibrosis (21). Therefore, the HYP level was another critical index for evaluating hepatic fi-
brosis. As shown in Fig. 2, the level of HYP was higher in the model group than in the 
control group (p < 0.05). Detection after drug treatment indicated that the HYP level was 
significantly decreased in the three amygdalin-treated groups compared with the model 
group (p < 0.05). However, only the middle- and high-dose groups did not differ signifi-
cantly from the control group. A comparison between the drug administration group and 
the positive drug-treated group revealed that there was no significant difference in the 
level of HYP. This result might indicate that amygdalin and silymarin had the same effect 
on liver fibrosis in rats.
Effects of amygdalin on the liver fibrosis indexes HA, LN, PC-III, and IV-C
The stages of hepatic fibrosis are correlated with the serum levels of HA, LN, PC-III, and 
IV-C, which are markers that are used to detect the degree of hepatic fibrosis (22). It has been 
reported that HA is a major resource for the extracellular matrix. PC-III is a marker used in 
the diagnosis of hepatic fibrosis and early cirrhosis (23). The serum levels of LN and IV-C 
are indexes of the rate of basement membrane turnover and indicate the degree of fibrosis 
in the portal area and sinusoidal capillaries (24). The results of these four indicators are 
shown in Fig. 2. The serum levels of the liver fibrosis indictors HA, LN, PC-III, and IV-C were 
significantly increased in the model group compared with the control group (p < 0.05). The 
Fig. 2. Liver function indexes in the serum or liver tissues: * significant from control p < 0.05; # sig-
nificant from model p < 0.05;   significant from silymarin p < 0.05.
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indexes of HA and IV-C were significantly decreased by amygdalin in the middle-dose 
group compared to the model group (p < 0.05). Furthermore, the LN level was significantly 
lower in the middle- and high-dose amygdalin-treated groups than in the model group (p < 
0.05). Only the PC-III indicator values were significantly decreased by the three doses of 
amygdalin in the treatment groups, compared to the model group (p < 0.05). Furthermore, 
the PC-III indicator values of the amygdalin treatment groups did not significantly differ 
from those of the control group. A comparison between the drug administration group and 
the positive drug group showed that the serum levels of the liver fibrosis indictor HA 
showed significant differences at all three doses (p < 0.05). All these results showed that 
amygdalin from A. mongolica alleviated the extent of hepatic fibrosis to varying degrees.
Effects of amygdalin on the activity of SOD and MDA
Oxidative stress is related to liver fibrosis and precedes hepatic stellate cells (HSC) ac-
tivation (25). The alteration in the MDA and SOD levels in the liver and serum is considered 
an index of collagen metabolism and provides valuable information about the biochemical 
and pathological events in hepatic fibrosis (26). To evaluate the degree of liver damage, we 
detected the activities of SOD and MDA in the serum and liver tissues. As shown in Fig. 3, 
the SOD activity in the serum and liver tissue was significantly lower in the model group 
than in the control group. Assessing the drug efficacy based on this model, the different 
Fig. 3. The active of SOD and the content of MDA in serum and liver: * significant from control p < 
0.05; # significant from model p < 0.05;  significant from silymarin p < 0.05.
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amygdalin doses significantly increased the SOD activity levels in the serum and liver tis-
sues of the treatment groups, compared with those in the model group. However, only the 
high-dose group differed significantly from the model group (p < 0.05), and it was not sig-
nificantly different from the control group. As shown in Fig. 3, the MDA levels in the serum 
and liver tissue samples of the model group were significantly increased compared to those 
in the serum and liver samples of the control group (p < 0.05). Detection after drug treatment 
indicated that the serum and liver samples of the low-, middle-, and high-dose amygdalin- 
-treated groups and the silymarin-treated group had significantly decreased MDA levels 
compared with those of the model group. Compared with those in the silymarin group, the 
activities of SOD and MDA in the serum showed no significant differences. However, the 
activity of SOD in the low- and middle-dose groups and MDA in the high-dose group 
showed significant differences in the liver tissues (p < 0.05). All these results indicate that 
amygdalin from A. mongolica alleviated hepatic fibrosis by regulating the activities of SOD 
and MDA in the antioxidant system.
Effect of amygdalin on liver pathology in rats with hepatic fibrosis
The histopathological analysis by H&E staining indicated different degrees of fibrosis 
in the liver tissues except in those of the control group. However, there were significant 
differences between the drug treatment groups and the model group (Fig. 4). We detected 
Fig. 4. Effect of amygdalin on liver pathology in rats with hepatic fibrosis). A: HE staining, 100-fold; 
B: Masson’s staining, 100-fold; a) control group, b) model group, c) low dose group, d) middle dose 
group, e) high dose group, f) silymarin group.
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many liver abnormalities in the model group, including the destruction or disappearance 
of lobular structures, large deposits of collagen fibers in the catheter area and interlobular 
area, liver lobules resegmented by fibrous strands, the formation of nodular pseudolobuli, 
severe steatosis in hepatocytes complicated with moderate edema, and necrosis (Fig. 4A-b). 
The histopathological changes were alleviated in the drug-treated groups, as observed by 
pseudolobuli formation and decreased collagen fiber deposition compared to those fea-
tures in the model group (Fig. 4A-c,d,e,f).
Histopathological analysis by Masson staining showed that the control group had the 
following characteristics: hepatocytes arranged radially around the central vein, normal 
structure of hepatic lobules and hepatocytes, and only a small amount of collagen fibers 
present in the portal area (Fig. 4B-a). In contrast, there were many liver abnormalities in 
the model group, including the destruction or disappearance of hepatic lobules, large 
depo sits of collagen fibers in the catheter area and interlobular area, and formation of 
nodular pseudolobuli (Fig. 4B-b). The observed histopathological abnormalities of the 
model group were alleviated in the drug-treated groups, as observed by pseudolobuli 
formation and decreased collagen fiber deposition (Fig. 4B-c,d,e,f).
All the results of the liver histopathological analysis showed that HE and Masson’s 
trichrome staining revealed normal liver tissues with distinct hepatic lobules and pseu-
dolobuli. The liver tissue structure in the model group was disordered, and the liver tis-
sues were replaced by a large amount of connective tissue. However, significant improve-
ment was observed in the drug-treated groups compared to the model group.
Fig. 5. The expression of TNF-α, TGF-β1, Smad 3, and Smad 7: * significant from control p < 0.05; # 
significant from model p < 0.05.
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Differential expression analysis of the hepatic fibrosis-related genes TNF-α, TGF-β, 
Smad 3, and Smad 7
Various chemokines are critical mediators of progressive liver damage and fibrosis 
development (27, 28). Tumor necrosis factor α (TNF-α) is a cytokine-induced by fibrosis, 
and its expression levels are positively correlated with the degree of fibrosis (29). Previous 
findings have shown that TGF-β and the Smad signal transduction pathway are closely 
associated with the genesis and development of hepatic fibrosis (30, 31). As shown in Fig. 
5, the expression of TNF-α was significantly increased in the model group compared to the 
control group (p < 0.05). Administration of different doses of amygdalin significantly redu-
ced the expression levels of TNF-α in the treatment groups compared with those in the 
model group (p < 0.05). Smad proteins transduce signals from TGF-β to regulate cell pro-
liferation, differentiation, and cell death activating of receptor serine/threonine kinases. 
As shown in Fig. 5, the expression levels of TGF-β, Smad 3, and Smad 7 were significantly 
increased in the model group, compared to the control group (p < 0.05). Importantly, each 
amygdalin dose significantly decreased the expression levels of TGF-β, Smad 3, and Smad 
7 compared with those in the model group (p < 0.05). Therefore, these data showed at the 
molecular level that amygdalin from A. mongolica regulated the process of hepatic fibrosis.
CONCLUSIONS
In this study, amygdalin was isolated from A. mongolica seeds and identified. The 
antifibrotic effect of amygdalin on hepatic fibrosis induced by CCl4 in rats was demon-
strated. The histopathological data showed that amygdalin from A. mongolica had a sig-
nificant protective effect against hepatic fibrosis. This study provides scientific guidance 
for the further development of amygdalin from A. mongolica as a potential therapeutic 
agent in the prevention and treatment of hepatic fibrosis.
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